Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Abiraterone acetate tablets (Yonsa) - selected U.S. label sections
Product / population
YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.
Renal method
Qualitative renal-impairment statement
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
A study dose is not this formulation's prescribing dose
The RX renal section cites a study using another abiraterone product.
What to reconcile: Do not import the other product's study dose as the YONSA regimen.
Source difference identified; final patient-specific adjudication required.
U.S. product labeling / DailyMed · YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.
Renal method: Qualitative renal-impairment statement Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal impairment comment
The YONSA label does not require a dose modification for renal impairment. Use the YONSA-specific treatment regimen and accompanying therapy rather than substituting another abiraterone product regimen.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.